Control Bionics Ltd. · ASX:CBL
Control Bionics — LSI Asia July 2026
12 slides from Control Bionics's conference presentation, Jul 1, 2026
Slide 1: Empowerment Through Proven Neurotechnology
Empowerment Through Proven Neurotechnology For personal use only LSI ASIA JULY 2026 JEREMY STEELE CHIEF EXECUTIVE OFFICER
Slide 2: The Body Is Already Speaking - We Built the Ears
The Body Is Already Speaking - We Built the Ears For personal use only Surface Electromyography (sEMG) is a non- invasive technique used to measure and record the electrical activity of muscles through sensors on the skin. Intent detection is the process of using muscle electrical signals to predict
Slide 3: Proven in the Hardest Clinical Use Case
Proven in the Hardest Clinical Use Case 25 Yearsof Clinical Validation For personal use only 1,000s of Customers 9 Patents + Provisionals Ryoka Hatakeyama Osaka, Japan FDA, TGA, CERegistered Devices 24 years old
Slide 4: From Device Company to Neural-Signal Platform
From Device Company to Neural -Signal Platform For personal use only Peter Ford (Founder of Control Bionics, left) and NeuroStrip Platform, 2026. Professor Stephen Hawking, 2002.
Slide 5: One Platform, Three Commercial Pillars
One Platform, Three Commercial Pillars For personal use only Assistive Communication Platform & Medical Technology Our Proven Cash Engine. The Data Moat. The Strategic Optionality. NeuroTechSolutions The Same Signal. A $4.2B Market.
Slide 6: Assistive Communication: Cash Engine
Assistive Communication: Cash Engine US$1BN Global Market that is For personal use only growing >10% perannum* Dedicated HCPCS funding code for streamlined US reimbursement pathway Funding provided in the biggest global markets: US, Australia, UK & Germany * Based on a report by The Business Researc
Slide 7: NeuroTech Solutions: Growth Engine
NeuroTech Solutions: Growth Engine Elite Sport Rehabilitation Power athlete performance by integrating sEMG utilization within a rehabilitation For personal use only clinical-grade data in a wearable form setting improves patient outcomes and factor. engagement. >$2BN Market Size* >$2.2BN Market Siz
Slide 8: From the Pitch to the Clinic: Three Use Cases, One Platform
From the Pitch to the Clinic — Three Use Cases, One Platform For personal use only Performance Monitoring Athlete Profiling Return-to-Play Measure real- time Longitudinal signal and Objective readiness metrics, neuromuscular load. performance baselines. not just guesswork.
Slide 9: Watch our NeuroTech in action
Watch our NeuroTech in action For personal use only
Slide 10: Platform & Medical Technology: Data, Apple BCI, Research
Platform & Medical Technology: Data, Apple BCI, Research For personal use only Proprietary Dataset Apple BCI Research Partnerships 25 years of unmatched Positioned at thecentre of Academic validation. clinical-grade sEMG. the BCI ecosystem. Data that matters.
Slide 11: Why now?
Why now? Control Bionics has 25 years of R&D in markets that are now primed for explosive growth. For personal use only CBL sEMG hardware and Regulatory and software driving increased and BCI Investment Boom reimbursement diversified use of this technology environment maturing AI demand for high - C
Slide 12: Proven tech. Commercial Traction. Global Scaling
Proven tech. Commercial Traction. Global Scaling GLOBAL VALIDATION AND 25 YEAR OLDMOAT For personal use only GROWING CORE BUSINESS ACROSS MAJOR MARKETS JEREMY STEELE CLEAR PATH TO SCALE AND PROFITABILITY CHIEF EXECUTIVE OFFICER JSTEELE@CONTROLBIONICS.COM TARGETING LARGE, UNMET MARKET NEEDS AUS:+6143